Foundation Fighting Blindness

08/28/2026

Spotlight on Leber congenital amaurosis (LCA) 👁️‍🗨️

Research is changing what's possible for people with LCA. LUXTURNA®, the first FDA-approved gene therapy for an inherited disease, treats LCA2 caused by mutations in the RPE65 gene.

Today, genetic medicines for six types of LCA (LCA1, LCA2, LCA4, LCA5, LCA10, and LCA13) are being evaluated in clinical trials, bringing hope for additional treatment options in the future.

The Foundation Fighting Blindness is proud to help drive this research forward! For the latest advances in LCA research, visit our website at: https://bit.ly/3WCf0q7

Image Description: Dark blue background with Foundation Fighting Blindness and Spotlight on Leber Congenital Amaurosis logo in top left corner. Text below reads, "Genetic medicines for six types of LCA are being evaluated in clinical trials." Six green circles below list the six types of LCA: LCA1, LCA2, LCA4, LCA5, LCA10, and LCA13. A small tag above the LCA2 circle reads, "LUXTURNA®."

08/27/2026

Spotlight on Leber congenital amaurosis (LCA) 👁️‍🗨️

This Children's Eye Health and Safety Month, we're raising awareness of LCA, which often causes severe vision loss or blindness within a child's first year of life. Every child's experience is different, but early signs, like a lack of visual responsiveness, are often the first clue for families.

A genetic test can provide a definitive diagnosis, helping families understand what's causing their child's vision loss and connecting them to the research shaping LCA's future, including emerging treatments and clinical trials.

Learn more about LCA at: www.FightingBlindness.org/diseases/leber-congenital-amaurosis-lca

Image Description: A young mother holding her toddler daughter on her lap while looking together at a tablet screen. Dark blue banner in the top left corner with the Foundation Fighting Blindness and Spotlight on Leber Congenital Amaurosis logo. Three dark blue circles stacked vertically with an arrow pointing from top to bottom along the left side, each with an icon depicting genetic testing, then diagnosis, then clinical trials.

08/26/2026

This National Dog Day, we're honoring guide dogs like Luna and the people whose lives they transform.

Meredyth was diagnosed with retinitis pigmentosa at 32, after years of unexplained symptoms and specialist visits. In 2022, she applied for a guide dog through Leader Dogs for the Blind, and after months of paperwork and three weeks of training, she finally met Luna and knew instantly she'd found her match.

"She's literally me in a dog," says Meredyth.

Read Meredyth and Luna's story at: www.FightingBlindness.org/stories/lead-with-luna-199

Image Description: [All slides] Dark blue background with Foundation Fighting Blindness logo and "National Dog Day" in the top left. [Slide one] Meredyth and Luna posing together with a teal and green gradient border and text on the bottom right that reads, "Meet Luna: A guide dog who gave Meredyth her independence back." [Slide two] Luna is sitting in a photo frame at a Foundation Fighting Blindness event with a teal and green gradient border. Text at the bottom reads, "Trained for the Job: Luna was matched with Meredyth through Leader Dogs for the Blind." [Slide three] Luna sitting beside Meredyth and another participant at a VisionWalk event outdoors, surrounded by a teal and green gradient border. Text at the bottom reads, "On the Job: Luna guides Meredyth around obstacles, stops at curbs and stairs, and alerts her to hazards." [Slide four] Meredyth holding Luna on a boat with water, mountains, and a glacier in the background, surrounded by a teal and green gradient border. Text at the bottom reads, "Partners for Life: Luna goes everywhere with Meredyth." [Slide five] Large white and green text fills the center with a quote, "As soon as they brought Luna to me, I knew she was my dog. She’s literally me in a dog." Meredyth's name appears below the quote.

08/25/2026

Spotlight on Leber congenital amaurosis (LCA) 👁️‍🗨️

In recognition of Children's Eye Health and Safety Month, we're shining a light on LCA, a group of inherited retinal dystrophies that often present within the first year of life, causing severe vision loss or blindness.

LCA isn't a single disease—it's caused by mutations in at least 25 different genes, highlighting the genetic complexity of LCA.

By raising awareness and supporting research, we're helping drive progress toward more treatments and cures for LCA and many other blinding diseases.

Learn more about LCA at: https://bit.ly/3WCf0q7

Image Description: Dark blue background with the Foundation Fighting Blindness and “Spotlight on Leber congenital amaurosis” logos in the top left corner. Text below reads, "Did you know? Mutations in at least 25 different genes can each cause LCA."

08/24/2026

This week, we're shining a Spotlight on Leber congenital amaurosis (LCA)—starting with Jackson Kennedy.

At age 9, Jackson received LUXTURNA®, the first FDA-approved gene therapy for an inherited retinal disease. Before treatment, he used a white cane, read and wrote in Braille, and often walked into walls because he couldn't see them.

After treatment, Jackson saw ice cubes in a glass for the first time, watched traffic from a hotel window, and even discovered what his dad looked like while chewing.

Jackson still lives with low vision, but LUXTURNA gave him the opportunity to see and experience a world that once seemed out of reach.

Read Jackson’s Beacon Story and discover how treatment changed his life at: https://bit.ly/4wDjTz2

Video Description: Jackson speaking directly to the camera discussing his journey with LCA.

08/21/2026

We’re officially ONE MONTH OUT from the start of our VisionWalk fall season! 🎉

From coast to coast, our VisionWalk community is coming together to raise funds, build awareness, and support research toward treatments and cures for blinding diseases. We can’t wait to walk alongside you this fall!

We're also excited to announce the winner of our Team Captain Challenge: Eric Bennardo of Team We See Hope in Pittsburgh!

Congratulations, Eric, and thank you to every team captain helping lead the way this VisionWalk season!

Register for your local walk today at www.VisionWalk.org

Image Description: Eric stands with three other team members (one male, two female) surrounding a large mascot of a man wearing a blue and yellow hat and matching flannel, holding a sign that reads "We See Hope."

08/20/2026

Life gets busy, and estate planning is one of those things that's easy to put off.

National Make-A-Will Month is the perfect reminder to create or update your will. Getting started is often easier than people expect—and our free Estate Planning Guide can help.

If you'd like your legacy to include advancing research toward treatments and cures for blinding diseases, we're here to help you take the first step.

Download your free Estate Planning Guide: www.FightingBlindness.org/estateplanningguide

Image Description: A mother sitting at a desk looking at a laptop and writing with a pen. A young daughter hugs the mother from behind. Both are smiling. Dark blue banner in the top left corner with the Foundation Fighting Blindness logo and text to the right that reads "August is National Make-A-Will Month." Text below reads "Leave your legacy. Ensure that progress continues for future generations."

08/20/2026

What does “high risk” really mean when it comes to developing new treatments? According to Dr. Alicia Kemble, about 90% of results from academia and biotech programs fail to make it through the drug development process.

On the latest episode of the Eye on the Cure, host Maddie Mossman sits down with Dr. Kemble, Senior Venture Associate with the RD Fund, to explore why drug development is especially risky in rare disease—and how venture philanthropy can help.

Hear more about the risks behind developing potential treatments and what it takes to move promising ideas forward: https://bit.ly/4fXQQBl

Video Description: Dr. Alicia Kemble is side by side with Maddie Mossman discussing what high risk really means in terms of developing treatments and cures for blinding diseases.

08/18/2026

Could a pair of smart glasses help make everyday tasks a little easier?

In this week's , Hadley and the Foundation Fighting Blindness show how Hadley's practical help specialist, Steve Kelley, uses Meta glasses to identify everyday items like spice containers with a simple voice command.

Watch the video to see this helpful accessibility tool in action!

Video Description: Steve demonstrates step by step how Meta glasses help him identify spice containers. The reel ends with "Tech Tip Tuesday" at the top, an artistic image of Steve, "Hey, Meta..." beneath his photo, and the Hadley and Foundation Fighting Blindness logos.

08/14/2026

As we recognize National Make-A-Will Month, we're celebrating the supporters who have chosen to leave a lasting legacy through the Foundation Fighting Blindness.

If you've already included the Foundation in your will or estate plans, thank you! Your generosity helps advance research toward treatments and cures for blinding diseases and continues to bring hope to future generations.

If you've already made this commitment, we'd love to know! Completing our confidential Legacy Giving Form allows us to ensure we understand your wishes and welcome you into our Legacy Society.

Complete the Legacy Giving Form: www.FightingBlindness.org/legacy-giving-form

Image Description: Two grandparents and their granddaughter pose together, smiling, in a stackpile-like hug with the grandfather on the bottom, then granddaughter, then grandmother on top. Dark blue banner in the top left corner with the Foundation Fighting Blindness logo and text to the right that reads "August is National Make-A-Will Month." Text below reads "Your legacy brings hope to future generations."

Keeping us informed of your legacy intensions helps the Foundation Fighting Blindness plan our investments in retinal disease research.